Accéder au contenu
Merck
  • Effect of remote ischaemic preconditioning on clinical outcomes in patients undergoing cardiac bypass surgery: a randomised controlled clinical trial.

Effect of remote ischaemic preconditioning on clinical outcomes in patients undergoing cardiac bypass surgery: a randomised controlled clinical trial.

Heart (British Cardiac Society) (2014-09-26)
Luciano Candilio, Abdul Malik, Cono Ariti, Matthew Barnard, Carmelo Di Salvo, David Lawrence, Martin Hayward, John Yap, Neil Roberts, Amir Sheikh, Shyam Kolvekar, Derek J Hausenloy, Derek M Yellon
RÉSUMÉ

Remote ischaemic preconditioning (RIPC), using brief cycles of limb ischaemia/reperfusion, is a non-invasive, low-cost intervention that may reduce perioperative myocardial injury (PMI) in patients undergoing cardiac surgery. We investigated whether RIPC can also improve short-term clinical outcomes. One hundred and eighty patients undergoing elective coronary artery bypass graft (CABG) surgery and/or valve surgery were randomised to receive either RIPC (2-5 min cycles of simultaneous upper arm and thigh cuff inflation/deflation; N=90) or control (uninflated cuffs placed on the upper arm and thigh; N=90). The study primary end point was PMI, measured by 72 h area under the curve (AUC) serum high-sensitive troponin-T (hsTnT); secondary end point included short-term clinical outcomes. RIPC reduced PMI magnitude by 26% (-9.303 difference (CI -15.618 to -2.987) 72 h hsTnT-AUC; p=0.003) compared with control. There was also evidence that RIPC reduced the incidence of postoperative atrial fibrillation by 54% (11% RIPC vs 24% control; p=0.031) and decreased the incidence of acute kidney injury by 48% (10.0% RIPC vs 21.0% control; p=0.063), and intensive care unit stay by 1 day (2.0 days RIPC (CI 1.0 to 4.0) vs 3.0 days control (CI 2.0 to 4.5); p=0.043). In a post hoc analysis, we found that control patients administered intravenous glyceryl trinitrate (GTN) intraoperatively sustained 39% less PMI compared with those not receiving GTN, and RIPC did not appear to reduce PMI in patients given GTN. RIPC reduced the extent of PMI in patients undergoing CABG and/or valve surgery. RIPC may also have beneficial effects on short-term clinical outcomes, although this will need to be confirmed in future studies. ClinicalTrials.gov ID: NCT00397163.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Phosphate de sodium dibasic dodecahydrate, meets analytical specification of Ph. Eur., BP, E339, 98.5-102.5% (T)
Sigma-Aldrich
Dibutyl phthalate, 99%
Sigma-Aldrich
Phosphate de sodium dibasic dodecahydrate, BioXtra, ≥99.0% (T)
Sigma-Aldrich
Phosphate de sodium dibasic dodecahydrate, puriss. p.a., crystallized, ≥99.0% (T)
Sigma-Aldrich
Phosphate de sodium dibasic dodecahydrate, JIS special grade, ≥99.0%
Supelco
Dibutyl phthalate, PESTANAL®, analytical standard
Sigma-Aldrich
Phosphate de sodium dibasic dodecahydrate, tested according to Ph. Eur.
Supelco
Dibutyl phthalate, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Sigma-Aldrich
Phosphate de sodium dibasic dodecahydrate, SAJ first grade, ≥98.0
Dibutyl phthalate, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Dibutyl phthalate, SAJ special grade, ≥98.0%